Coronavirus

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress

Initiated the global Phase 2 study of NTLA-2002, a CRISPR-based, potential single-dose treatment for hereditary angioedema (HAE)Submitted IND application for...

Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)

Final draft guidance based on cost effectiveness evaluation of sotrovimabSAN FRANCISCO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc....

TransCode Therapeutics and BRAIN Biotech join forces to develop a CRISPR-derived technology platform for cancer treatment

BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively...

Nature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral Drug

BOSTON, MASSACHUSETTS, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing...

eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID

Results presented at 30th Conference on Retroviruses and Opportunistic Infections (CROI)SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 21, 2023...

Sorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)

SAN DIEGO, Feb. 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted an IRS Form 8937...

Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...

Aligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver

SOUTH SAN FRANCISCO, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...

Hillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breast Cancer, Gastric Cancer, Lung Cancer and Ovarian Cancer

Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Murine Anti-SARS-CoV-2 Monoclonal Antibodies

Immunocompromised Individuals, Including Organ Transplant Recipients, Are at Increased Risk of Severe COVID-19 and Poor Clinical Outcomes SARS-CoV-2 has Mutated...

error: Content is protected !!